Please login to the form below
BeiGene
This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.
BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
In the ORR analysis conducted by the independent review committee (IRC), BeiGene’s drug demonstrated non-inferiority in the interim analysis. ... consistent safety advantages for these patients,” said Jane Huang, chief medical officer, Haematology at
Latest news
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
Detailed results from the study will be presented at an upcoming medical conference, BeiGene said in a statement. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung cancer (NSCLC).
-
FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma
In China, BeiGene’s is approved for pretreated MCL patients as well as pretreated chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) patients. ... BeiGene revealed in a statement that the FDA has set a prescription drug user fee
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license
-
Merck expands partnership with Zymeworks for multispecific antibodies
Chinese pharma BeiGene also owns the rights to Zanidatamab and ZW49 in a number of East Asian countries including China and South Korea as well as Australia and New Zealand.
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
Merck expands partnership with Zymeworks for multispecific antibodies
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
More from news
Approximately 14 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
-
Biopharma's Future: Made in China
The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
-
Deal Watch March 2017
In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
-
Deal Watch table for November 2013
BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.
Chinese biotech’s global ambitions
Biopharma's Future: Made in China
Deal Watch March 2017
Deal Watch table for November 2013
More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.
New hires at EMA, Gilead and BeiGene
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Valneva COVID-19 vaccine more effective than AZ
- Real-world data highlights flu vaccine efficacy
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- How do you define a biotech company?
- Attracting the best talent to build Lucid’s future
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
